Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Atezolizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260130221586/en/Exelixis-Announces-U.S.-FDA-Accepted-the-New-Drug-Application-for-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-for-Patients-with-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    Natera Submits Signatera CDx PMA to FDA
    Natera Submits Signatera CDx PMA to FDA

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260129560151/en/Natera-Submits-Signatera-CDx-PMA-to-FDA

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    Oncolytics Biotech Reveals Pelareorep Plus Atezolizumab Efficacy
    Oncolytics Biotech Reveals Pelareorep Plus Atezolizumab Efficacy

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216966/0/en/Oncolytics-Biotech-Announces-Updated-Clinical-Data-from-GOBLET-Cohort-4-Demonstrating-Activity-of-Pelareorep-Plus-Atezolizumab-in-Third-Line-Anal-Cancer.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Chugai's Tecentriq Approved In Japan For Thymic Carcinoma
    Chugai's Tecentriq Approved In Japan For Thymic Carcinoma

    27 Dec 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/chugais-tecentriq-gets-green-light-in-japan-for-hard-to-treat-thymic-carcinoma-18691

    INDPHARMAPOST
    27 Dec 2025
    Share Share
    KaliVir & Roche Partner To Test VET3-TGI With Atezolizumab
    KaliVir & Roche Partner To Test VET3-TGI With Atezolizumab

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251119270996/en/KaliVir-Immunotherapeutics-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Roche-to-Evaluate-VET3-TGI-in-Combination-with-Atezolizumab-Tecentriq-in-Advanced-Solid-Tumors

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    Xilio Reports Late-Breaking Ph2 Vilastobart Data In MSS mCRC
    Xilio Reports Late-Breaking Ph2 Vilastobart Data In MSS mCRC

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183723/0/en/Xilio-Therapeutics-Announces-Late-Breaking-Phase-2-Data-for-Vilastobart-in-Patients-with-MSS-mCRC-and-High-Plasma-Tumor-Mutational-Burden-at-Society-for-Immunotherapy-of-Cancer-SIT.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.